May 26, 2024


You are Your Only Limit

Puma Biotechnology Experiences Inducement Awards Beneath Nasdaq Listing Rule 5635(c)(4)

2 min read

LOS ANGELES–(Enterprise WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical firm, introduced that on June 3, 2022, the Compensation Committee of Puma’s Board of Administrators accepted the grant of inducement restricted stock device awards masking 38,125 shares of Puma common stock to six new non-executive workforce.

The awards ended up granted beneath Puma’s 2017 Work Inducement Incentive Award Plan, which was adopted on April 27, 2017 and offers for the granting of equity awards to new staff members of Puma. The restricted inventory device awards vest above a 3-year period of time, with one-third of the shares fundamental every award vesting on the initial anniversary of the award’s vesting commencement date, June 1, 2022, and just one-sixth of the shares fundamental every award vesting on each six-thirty day period anniversary of the vesting commencement date thereafter, subject to ongoing services. The awards had been granted as an inducement product to the new workforce coming into into work with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical firm with a target on the improvement and commercialization of innovative items to enhance most cancers care. Puma in-licenses the world-wide development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was permitted by the U.S. Food stuff and Drug Administration in 2017 for the extended adjuvant treatment method of grownup people with early stage HER2-overexpressed/amplified breast cancer, next adjuvant trastuzumab-dependent remedy, and is promoted in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the Fda in blend with capecitabine for the remedy of adult clients with innovative or metastatic HER2-good breast cancer who have acquired two or much more prior anti-HER2-primarily based regimens in the metastatic setting. NERLYNX was granted promoting authorization by the European Commission in 2018 for the extended adjuvant procedure of grownup patients with early stage hormone receptor-optimistic HER2-overexpressed/amplified breast most cancers and who are significantly less than just one yr from completion of prior adjuvant trastuzumab-based remedy. NERLYNX is a registered trademark of Puma Biotechnology, Inc. All rights reserved. | Newsphere by AF themes.